Bio-Path Holdings, Inc. (NASDAQ:BPTH) Short Interest Down 54.0% in October

Bio-Path Holdings, Inc. (NASDAQ:BPTH) was the target of a significant drop in short interest during the month of October. As of October 15th, there was short interest totaling 6,900 shares, a drop of 54.0% from the September 30th total of 15,000 shares. Approximately 0.1% of the shares of the stock are sold short. Based on an average trading volume of 77,000 shares, the short-interest ratio is presently 0.1 days. Based on an average trading volume of 77,000 shares, the short-interest ratio is presently 0.1 days. Approximately 0.1% of the shares of the stock are sold short.

Bio-Path Trading Down 3.3%

Shares of BPTH stock opened at $0.09 on Thursday. The company has a market capitalization of $831,780.00, a price-to-earnings ratio of -0.05 and a beta of -0.08. The firm has a 50-day moving average price of $0.08 and a 200 day moving average price of $0.14. Bio-Path has a twelve month low of $0.05 and a twelve month high of $3.39.

About Bio-Path

Bio-Path Holdings, Inc operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction.